Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Unattributed | Alive

Total Raised


Last Raised

$1M | 11 yrs ago

About Koronis Pharmaceuticals

Koronis Pharma develops antiviral therapeutics based on Viral Decay Acceleration, which exploits the strength of a virus to target its collapse.

Koronis Pharmaceuticals Headquarters Location

800 Fifth Avenue Suite 4120

Seattle, Washington, 98104,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Koronis Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Koronis Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Koronis Pharmaceuticals Patents

Koronis Pharmaceuticals has filed 5 patents.

patents chart

Application Date

Grant Date


Related Topics




Prodrugs, Vaccines, Animal viral diseases, Animal virology, Virology


Application Date


Grant Date



Related Topics

Prodrugs, Vaccines, Animal viral diseases, Animal virology, Virology



Latest Koronis Pharmaceuticals News

Venture-backed Koronis Plans I.P.O.

Mar 14, 2011

March 14, 2011 Koronis Pharmaceuticals, a venture-backed developer of drugs for HIV, is planning an initial public offering in London for later this year, or early 2012, Reuters reported. Seattle-based Koronis has raised $43 million to date from investors. It is majority-owned by Pacific Horizon Ventures, a Seattle-based venture capital firm, Reuters said. The company’s drugs are designed to accelerate mutation of the virus that causes AIDS to the point where it collapses, Reuters wrote. (Reuters) – Koronis Pharmaceuticals, a privately held U.S. biotech firm working on a new kind of HIV drug, is looking to list in London later this year or early in 2012, its chief executive said. Seattle-based Koronis — pioneering a new HIV drug designed to accelerate mutation of the virus that causes AIDS to the point where it collapses — needs around $15 million to take its experimental product to the next stage of clinical tests. CEO Donald Elmer said he had been in talks with banks in London because raising small sums of that size was no longer feasible on the Nasdaq market in the United States, given the heavy costs of maintaining a listing there. He aims to raise the cash needed to take Koronis’s “viral decay acceleration” drug KP-1461 into further mid-stage Phase II studies via either an initial public offering (IPO) on London’s Alternative Investment Market (AIM) or by reversing into a listed entity with a cash balance. “The practical problem today is that Nasdaq is out of reach for many companies that are at the size of Koronis and the AIM market is an ideal intermediate rung for company looking to raise 10-15 million pounds,” he said in a telephone interview. So far, KP-1461 has been tested in short clinical trials on around 80 patients with no ill-effect. Now Koronis needs to conduct longer-term tests to see if it really can reduce the amount of virus circulating in patients’ blood. If it works, the new drug could mark a major change in HIV/AIDS treatment. Existing drugs all work by suppressing virus function and must be taken in life-long cocktail combinations. KP-1461 would be the first non-suppressive therapy. Katherine Xu, an analyst at Wedbush Securities, said in a research note in January that the approach was potentially “game changing” for the $12 billion-a-year HIV market, although it was still at a very early stage and therefore highly uncertain. Leading players in HIV treatment at present include Gilead (GILD.O) and ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK.L) and Pfizer (PFE.N). Koronis has to date raised $43 million in a series of private fund-raisings. It is majority-owned by Pacific Horizon Ventures, a Seattle-based venture capital firm. (Editing by Louise Heavens) © 2015 Buyouts Insider / Argosy Group LLC

  • When was Koronis Pharmaceuticals founded?

    Koronis Pharmaceuticals was founded in 1998.

  • Where is Koronis Pharmaceuticals's headquarters?

    Koronis Pharmaceuticals's headquarters is located at 800 Fifth Avenue, Seattle.

  • What is Koronis Pharmaceuticals's latest funding round?

    Koronis Pharmaceuticals's latest funding round is Unattributed.

  • How much did Koronis Pharmaceuticals raise?

    Koronis Pharmaceuticals raised a total of $47.55M.

  • Who are the investors of Koronis Pharmaceuticals?

    Investors of Koronis Pharmaceuticals include Asset Management Ventures, Pacific Horizon Ventures, Johnson & Johnson Innovation, Johnson & Johnson, WRF Capital and 4 more.

  • Who are Koronis Pharmaceuticals's competitors?

    Competitors of Koronis Pharmaceuticals include Vasopharm, Profectus BioSciences, OyaGen, Eiger BioPharmaceuticals, Tobira Therapeutics, Conatus Pharmaceuticals, Lux Biosciences, Illumigen Biosciences, Panacos Pharmaceuticals, Marillion Pharmaceuticals and 12 more.

You May Also Like

Panacos Pharmaceuticals

Panacos is developing anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Per the company, Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.

Profectus BioSciences

Profectus Biosciences is a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases. The Company's name, Profectus, when translated from its Latin roots, means"to advance or improve". The Company's proof of concept target is human immunodeficiency virus (HIV) with an intermediate term focus on hepatitis C virus (HCV).

Lux Biosciences

Lux Biosciences is a clinical stage biotechnology company specializing in the development and commercialization of medications for serious ophthalmic diseases. With a product in NDA/MAA submission stage and several earlier-stage projects, Lux is building a high-growth, and sustainable ophthalmic company.


Apath is a pharmaceutical discovery and development company with a focus on the hepatitis C virus ("HCV") and other human viral pathogens. Apath was founded by Charles M. Rice, Ph.D., currently Professor of Molecular Microbiology, Rockefeller University and formerly of the Washington University (St. Louis) School of Medicine. Apath is engaged in the commercial application of virology and viral genetics to discover and develop a broad range of diagnostic and therapeutic products for viral infections, and for applications using viruses as vectors. Apath's primary focus is on RNA viruses. RNA viruses account for the majority of viruses which are human pathogens. In addition to HCV, they include several medically important viruses such as influenza, respiratory syncytial virus ("RSV"), and hemorrhagic fever viruses (e.g., Ebola).


Lifepharms is researching natural products for medicinal and agricultural uses, including anticancer and pox virus medications.

Opal Therapeutics

Opal Therapeutics is an immunotherapy company focused on therapies for human immunodeficiency virus (HIV) and Hepatitis C (HCV), based on technology from the University of Melbourne.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.